July 25th 2024
ConSynance Therapeutics' CSTI-500, an innovative Triple Monoamine Reuptake Inhibitor, has received FDA's Rare Pediatric Disease Designation for treating Prader-Willi Syndrome in children.
Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care
October 26, 2024
Register Now!
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
Clinical ShowCase™: Finding the Best Path Forward for Patients with COPD
View More
Surv.AI Says™: What Clinicians and Patients Are Saying About Glucose Management in the Technology Age
View More
A Tethered Approach to Type 2 Diabetes Care – Connecting Insulin Regimens with Digital Technology
View More
Prenatal exposure to analgesic opioid linked with elevated risk of ADHD
October 5th 2021A study has found that prenatal analgesic opioid exposure of 5 or more weeks is associated with a slightly elevated risk of attention-deficit/hyperactivity disorder (ADHD) in children compared to exposure of 4 weeks or less.
Hyperactivity, learning disabilities, and social isolation…COVID-19 and its effects on ADHD
October 26th 2020COVID-19 has created many stresses: mental, job-related, and health. For some caregivers, these stressors are complicated further with caring for a child with attention-deficit/hyperactive disorder (ADHD).
Role of relative immaturity in school and ADHD medication use
September 28th 2020Attention-deficit/hyperactivity disorder (ADHD) is marked by age-inappropriate levels of inattention and activity. A report from Finland examines how relative immaturity in the first years of school could increase the risk of ADHD medication use.